Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6761-6772

  Myburgh, Renier ^a,b   Ivic, Sandra ^a   Pepper, Michael S ^b   Gers Huber, Gustavo ^a   Li, Duo ^a   Audigé, Annette ^a   Rochat, Mary Aude ^a   Jaquet, Vincent ^c   Regenass, Stephan ^a   Manz, Markus G ^a   Salmon, Patrick ^c   Krause, Karl Heinz ^c   Speck, Roberto F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; LENTIVIRUS VECTOR; MICRORNA; CCR5 PROTEIN, HUMAN; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; ENGRAFTMENT; EX VIVO STUDY; FLOW CYTOMETRY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY; VIRAL TROPISM; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE RESISTANCE; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TRANSPLANTATION; VIROLOGY; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; DISEASE RESISTANCE; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; MICE, SCID; RECEPTORS, CCR5; RECEPTORS, HIV; TRANSPLANTATION; VIRAL LOAD; VIRUS ATTACHMENT;

EID: 84930888039     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00277-15     Document Type: Article

References (54)

1. Lohse N, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Nielsen L, Sorensen HT, Obel N. 2011. Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study. J Acquir Immune Defic Syndr 57:334-339. http://dx.doi.org/10.1097/QAI.0b013e31821d34ed.
2. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901-910. http://dx .doi.org/10.1056/NEJMoa1300662.
3. Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH. 2013. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121:1524-1533. http://dx.doi.org/10.1182/blood-2012-07-447250.
4. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA. 2010. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2:36ra43. http://dx.doi.org/10.1126/scitranslmed.3000931.
5. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. 2009. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15:285-292. http://dx.doi.org/10.1038/nm.1932.
6. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797. http://dx.doi.org/10.1006/mthe.2002.0611.
7. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD. 1996. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216-223. http://dx.doi.org/10.1038/nm0296-216.
8. Hütter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stemcell transplantation. N Engl J Med 360:692-698. http://dx.doi.org/10.1056/NEJMoa0802905.
9. Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, Trenschel R, Schadendorf D, Dittmer U, Esser S, Essen HIVAG. 2014. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 371:880-882. http://dx.doi.org/10.1056/NEJMc1405805.
10. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz MG. 2013. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 31:635-674. http://dx.doi.org/10.1146/annurev-immunol-032712-095921.
11. Nischang M, Gers-Huber G, Audige A, Akkina R, Speck RF. 2012. Modeling HIV infection and therapies in humanized mice. Swiss Med Wkly 142:w13618. http://dx.doi.org/10.4414/smw.2012.13618.
12. Bennett MS, Akkina R. 2013. Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses 5:3119-3141. http://dx .doi.org/10.3390/v5123119.
13. Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, Kittipongdaja P, Chen A, Bristol G, Galic Z, Zack JA, Yang O, Chen IS, Lee B, An DS. 2010. A highly efficient short hairpin RNA potently downregulatesCCR5expression in systemic lymphoid organs in thehu-BLTmouse model. Blood 115:1534-1544. http://dx.doi.org/10.1182/blood-2009-04-215855.
14. Ringpis GE, Shimizu S, Arokium H, Camba-Colon J, Carroll MV, Cortado R, Xie Y, Kim PY, Sahakyan A, Lowe EL, Narukawa M, Kandarian FN, Burke BP, Symonds GP, An DS, Chen IS, Kamata M. 2012. Engineering HIV-1-resistant T-cells from short-hairpin RNAexpressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One 7:e53492. http://dx.doi.org/10.1371/journal.pone.0053492.
15. Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, Anderson JS. 2012. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol 86:5719-5729. http://dx.doi.org/10.1128/JVI.06300-11.
16. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28:839-847. http://dx.doi .org/10.1038/nbt.1663.
17. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H. 2010. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 84:6645-6653. http://dx.doi.org/10.1128/JVI.02339-09.
18. Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA. 2012. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 8:e1002649. http://dx.doi.org/10.1371/journal.ppat.1002649.
19. Hauber I, Hofmann-Sieber H, Chemnitz J, Dubrau D, Chusainow J, Stucka R, Hartjen P, Schambach A, Ziegler P, Hackmann K, Schrock E, Schumacher U, Lindner C, Grundhoff A, Baum C, Manz MG, Buchholz F, Hauber J. 2013. Highly significant antiviral activity of HIV-1 LTRspecific tre-recombinase in humanized mice. PLoS Pathog 9:e1003587. http://dx.doi.org/10.1371/journal.ppat.1003587.
20. Barclay SL, Yang Y, Zhang S, Fong R, Barraza A, Nolta JA, Torbett BE, Abedi M, Bauer G, Anderson JS. 2015. Safety and efficacy of a tCD25 pre-selective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells. Stem Cells 33:870-879. http://dx.doi .org/10.1002/stem.1919.
21. Berkhout B, Liu YP. 2014. Towards improved shRNA and miRNA reagents as inhibitors of HIV-1 replication. Future Microbiol 9:561-571. http://dx.doi.org/10.2217/fmb.14.5.
22. Jackson AL, Linsley PS. 2004. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 20:521-524. http://dx.doi.org/10.1016/j.tig .2004.08.006.
23. Bibikova M, Golic M, Golic KG, Carroll D. 2002. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161:1169-1175.
24. Cho SW, Kim S, Kim JM, Kim JS. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31:230-232. http://dx.doi.org/10.1038/nbt.2507.
25. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. 2011. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29:143-148. http://dx.doi.org/10.1038/nbt.1755.
26. Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L. 2014. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510:235-240. http://dx.doi.org/10.1038/nature13420.
27. Sander JD, Ramirez CL, Linder SJ, Pattanayak V, Shoresh N, Ku M, Foden JA, Reyon D, Bernstein BE, Liu DR, Joung JK. 2013. In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. Nucleic Acids Res 41:e181. http://dx.doi.org/10.1093/nar/gkt716.
28. Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, Holmes MC, Gregory PD, Glimm H, Schmidt M, Naldini L, von Kalle C. 2011. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29:816-823. http://dx.doi.org/10.1038/nbt.1948.
29. Cradick TJ, Ambrosini G, Iseli C, Bucher P, McCaffrey AP. 2011. ZFN-site searches genomes for zinc finger nuclease target sites and offtarget sites. BMC Bioinformatics 12:152. http://dx.doi.org/10.1186/1471-2105-12-152.
30. Myburgh R, Cherpin O, Schlaepfer E, Rehrauer H, Speck RF, Krause KH, Salmon P. 2014. Optimization of critical hairpin features allows miRNA-based gene knockdown upon single-copy transduction. Mol Ther Nucleic Acids 3:e207. http://dx.doi.org/10.1038/mtna.2014.58.
31. Giry-Laterrière M, Verhoeyen E, Salmon P. 2011. Lentiviral vectors. Methods Mol Biol 737:183-209. http://dx.doi.org/10.1007/978-1-61779-095-9_8.
32. Nischang M, Sutmuller R, Gers-Huber G, Audige A, Li D, Rochat MA, Baenziger S, Hofer U, Schlaepfer E, Regenass S, Amssoms K, Stoops B, Van Cauwenberge A, Boden D, Kraus G, Speck RF. 2012. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS One 7:e38853. http://dx.doi.org/10.1371/journal.pone.0038853.
33. McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM, Francis DP, Hicks D, Kalyanaraman VS, Martin LS. 1985. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy- associated virus (LAV). J Immunol Methods 76:171-183. http://dx.doi.org/10.1016/0022-1759(85)90489-2.
34. Moore JP, Sattentau QJ, Clapham PR. 1990. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies. AIDS Res Hum Retroviruses 6:1273-1279.
35. Salminen MO, Koch C, Sanders-Buell E, Ehrenberg PK, Michael NL, Carr JK, Burke DS, McCutchan FE. 1995. Recovery of virtually fulllength HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology 213:80-86. http://dx.doi .org/10.1006/viro.1995.1548.
36. Fehse B, Kustikova OS, Bubenheim M, Baum C. 2004. Pois(s)on-it's a question of dose. Gene Ther 11:879-881. http://dx.doi.org/10.1038/sj.gt .3302270.
37. De Luca A, Teofili L, Antinori A, Iovino MS, Mencarini P, Visconti E, Tamburrini E, Leone G, Ortona L. 1993. Haemopoietic CD34_progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol 85:20-24. http://dx.doi.org/10.1111/j.1365-2141.1993.tb08640.x.
38. Milich L, Margolin B, Swanstrom R. 1993. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol 67:5623-5634.
39. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158. http://dx.doi.org/10.1126/science.1233158.
40. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee PP, Orange JS, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. 2013. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:1233151. http://dx.doi.org/10.1126/science.1233151.
41. McGarrity GJ, Hoyah G, Winemiller A, Andre K, Stein D, Blick G, Greenberg RN, Kinder C, Zolopa A, Binder-Scholl G, Tebas P, June CH, Humeau LM, Rebello T. 2013. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med 15:78-82. http://dx.doi.org/10.1002/jgm.2691.
42. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541. http://dx.doi.org/10.1038/nature04791.
43. An DS, Qin FX, Auyeung VC, Mao SH, Kung SK, Baltimore D, Chen IS. 2006. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 14:494-504. http://dx.doi.org/10.1016/j.ymthe.2006.05.015.
44. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC. 2011. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:1255-1263. http://dx.doi.org/10.1182/blood-2011-02-337360.
45. Dupré L, Trifari S, Follenzi A, Marangoni F, Lain de Lera T, Bernad A, Martino S, Tsuchiya S, Bordignon C, Naldini L, Aiuti A, Roncarolo MG. 2004. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther 10:903-915. http://dx.doi.org/10.1016/j.ymthe.2004.08.008.
46. Phaltane R, Lachmann N, Brennig S, Ackermann M, Modlich U, Moritz T. 2014. Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter. Biomaterials 35:7204 -7213. http://dx.doi.org/10.1016/j.biomaterials.2014.05.001.
47. Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC. 2013. Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy. PLoS One 8:e65519. http://dx.doi.org/10.1371/journal.pone.0065519.
48. Muñoz-Calleja C, Costantini A, Silvestri G, Butini L, Regnery CM, Mancini S, Montroni M. 2001. Highly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations. AIDS 15:1887-1890. http://dx.doi.org/10.1097/00002030-200109280-00022.
49. _/_ mice. Proc Natl Acad Sci U S A 103:15951-15956. http://dx.doi.org/10.1073/pnas.0604493103.
50. _/_ humanized mouse model. J Virol 84:2740-2752. http://dx.doi.org/10.1128/JVI.02180-09.
51. Herrera-Carrillo E, Liu YP, Berkhout B. 2014. The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS. Mol Ther 22: 596-606. http://dx.doi.org/10.1038/mt.2013.280.
52. Boutimah F, Eekels JJ, Liu YP, Berkhout B. 2013. Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors. Antiviral Res 98:121-129. http://dx.doi.org/10.1016/j .antiviral.2013.02.011.
53. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M, Buning H, Schwartz O, Knops E, Kaiser R, Seaman MS, Wilson JM, Rice CM, Ploss A, Bjorkman PJ, Klein F, Nussenzweig MC. 2013. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 110:16538-16543. http://dx.doi.org/10.1073/pnas.1315295110.
54. Palmer BE, Neff CP, Lecureux J, Ehler A, Dsouza M, Remling-Mulder L, Korman AJ, Fontenot AP, Akkina R. 2013. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol 190:211-219. http://dx.doi.org/10.4049/jimmunol.1201108.